Home | Welcome to Contract Pharma   
Last Updated Tuesday, May 26 2015


Financial Report: Teva

Published February 7, 2013

4Q Revenues: $5.2 billion (-8%)

4Q Earnings: $280 million (-44%)

FY Revenues: $20.3 billion (+11%)

FY Earnings: $1.9 billion (-31%)

Comments: Generic revenues in the quarter were $2.7 billion (including API sales of $202 million), down 11%. Specialty medicines revenue was $2.1 billion, down 7%. OTC sales of PGT Healthcare, a joint venture with Procter & Gamble, were $377 million, up 11%. Revenues in the U.S. in the quarter were $2.6 billion (50% of total revenues), down 14% mainly due to generic competition for Provigil. Revenues in Europe were $1.5 billion (29% of total revenues), up 2% driven by Copaxone following the take-back of marketing and distribution rights, as well as increased OTC sales. Rest of the World sales totaled $1.1 billion (21% of total revenues), down 3% as a result of the sale of certain businesses of Mepha AG, as well as weaker performance in Canada due to government-imposed price reforms.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On